Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Di Cosimo

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 9, 2025
Reliability of core needle biopsy for HER2-low early-stage breast cancerC M Ciniselli, P Verderio, V Duroni, et al.
Breast Cancer Research and Treatment|April 30, 2024
Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTOS Pizzamiglio, C M Ciniselli, E de Azambuja, et al.
Journal of Cancer Research and Clinical Oncology|January 17, 2022
Mammographic density to predict response to neoadjuvant systemic breast cancer therapyS Di Cosimo, C Depretto, R Miceli, et al.
Cytokine & Growth Factor Reviews|December 22, 2019
Anticancer innovative therapy: Highlights from the ninth annual meetingT Volpari, F De Santis, A P Bracken, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 3, 2019
Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patientsM C De Santis, E La Rocca, E Meneghini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2011
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysisJ Cortes, V Calvo, N Ramírez-Merino, et al.
ESMO Open|March 20, 2021
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapyE Ortolan, V Appierto, M Silvestri, et al.
Cytokine & Growth Factor Reviews|November 6, 2018
Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meetingF De Santis, M Del Vecchio, L Castagnoli, et al.
ESMO Open|June 18, 2025
Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trialA Llombart-Cussac, J M Pérez-García, M Bellet, et al.
NPJ Breast Cancer|December 2, 2025
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapyS Pizzamiglio, A Blanda, V Appierto, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|March 9, 2025
Reliability of core needle biopsy for HER2-low early-stage breast cancerC M Ciniselli, P Verderio, V Duroni, et al.
Breast Cancer Research and Treatment|April 30, 2024
Circulating microRNAs and therapy-associated cardiac events in HER2-positive breast cancer patients: an exploratory analysis from NeoALTTOS Pizzamiglio, C M Ciniselli, E de Azambuja, et al.
Journal of Cancer Research and Clinical Oncology|January 17, 2022
Mammographic density to predict response to neoadjuvant systemic breast cancer therapyS Di Cosimo, C Depretto, R Miceli, et al.
Cytokine & Growth Factor Reviews|December 22, 2019
Anticancer innovative therapy: Highlights from the ninth annual meetingT Volpari, F De Santis, A P Bracken, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 3, 2019
Axillary nodal involvement by primary tumor features in early breast cancer: an analysis of 2600 patientsM C De Santis, E La Rocca, E Meneghini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 7, 2011
Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysisJ Cortes, V Calvo, N Ramírez-Merino, et al.
ESMO Open|March 20, 2021
Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapyE Ortolan, V Appierto, M Silvestri, et al.
Cytokine & Growth Factor Reviews|November 6, 2018
Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meetingF De Santis, M Del Vecchio, L Castagnoli, et al.
ESMO Open|June 18, 2025
Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trialA Llombart-Cussac, J M Pérez-García, M Bellet, et al.
NPJ Breast Cancer|December 2, 2025
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapyS Pizzamiglio, A Blanda, V Appierto, et al.
Pageof 4